



61435_Auto_Edited.docx

Quotes Excluded
Bibliography Excluded12%
SIMILAR**Name of Journal:** *World Journal of Virology***Manuscript NO:** 61435**Manuscript Type:** REVIEW

Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID 19 compared with standard of care? A literature review

Anna Maria Spera. Sofosbuvir: An antiviral drug for a viral infection.

Anna Maria Spera

Match Overview

1	Internet 145 words crawled on 04-Oct-2020 onlinelibrary.wiley.com	4%
2	Internet 52 words crawled on 21-Oct-2020 academic.oup.com	1%
3	Crossref 30 words D.R. Panday, K.R. Pandey, G.P. Rauniar. "COVID-19: All ... acts, No Myth", Kathmandu University Medical Journal, 20	1%
4	Crossref 20 words Babak Sayad, Mahsa Sobhani, Reza Khodarahmi. "Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why	1% >
5	Crossref 20 words Bhagawaty Kalikotay. "Corona Virus Disease 2019 (COVID -19) Prevention and Control Measures in Community: A L ...	1%
6	Internet 19 words crawled on 26-Dec-2020 pubmed.ncbi.nlm.nih.gov	1%



ALL

IMAGES

VIDEOS

158,000 Results

Any time ▾

Potential Drugs and Remedies for the Treatment of COVID ...

<https://biologicalproceduresonline.biomedcentral.com/...> ▾

Abstract COVID-19 disease with a high rate of contagious and highly nonspecific symptoms, is an infectious disease caused by a newly discovered coronavirus. Most people who fall sick with COVID-19 will experience mild to moderate symptoms such as respiratory symptoms, cough, dyspnea, fever, and viral pneumonia and recover without any special cure. However, some others need special and ...

Estimated Reading Time: 8 mins

Treatment for COVID-19: An overview - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S0014299920307366>

The purpose of this multicentre study was to evaluate the efficacy of Tocilizumab treatment in addition to usual care in reducing mortality and the likelihood of invasive mechanical ventilation in a cohort of patients with severe COVID-19 pneumonia compared to the cohort of patients who received standard treatment.

Antivirals for COVID-19: A critical review - ScienceDirect

<https://www.sciencedirect.com/science/article/pii/S2213398420301767>

1. Introduction. The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to human civilization and leaves many challenges ahead. 1, 2 As of July 11, 2020, there were more than 12 million confirmed cases of COVID-19, with more than 500,000 deaths. 3 The most common symptoms of COVID-19 include ...

Literature-based review of the drugs used for the ...

<https://www.sciencedirect.com/science/article/pii/S2352081720300684>

Literature-based review of the drugs used for the treatment of COVID-19. ... studies are showing some clinical evidence and may expect the same with these clinical trials and this may become a potential treatment option for COVID-19 patients. 81. ... and 100 to the standard care group. They have observed a similar reduction in the viral loads ...

COVID-19 Monthly Update: Current COVID-19 Treatment ...

<https://www.powerpak.com/course/content/120583> ▾

The probability of superiority (Bayesian cumulative logistic model) in patients with severe COVID-19 was 93% and 80% for fixed-dosing and shock-dependent-dosing strategies, respectively, versus standard of care for organ support-free days.

Are nucleotide inhibitors, already used for treating hepatitis C virus



ALL

IMAGES

VIDEOS

67,900 Results

Any time ▾

Open links in new tab



[Provisional Guidance on the Use of Hepatitis C Virus ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404695>

Apr 01, 2012 · On 13 May 2011 and 23 May 2011, boceprevir (BOC) and telaprevir (TVR), respectively, were approved by the US Food and Drug Administration to be **used** with peginterferon and ribavirin **for treatment** of genotype 1 chronic **hepatitis C virus (HCV) infection**. **Use** of these NS3/4A serine protease **inhibitors** (PIs) with peginterferon and ribavirin ...

Cited by: 22

Author: David L. Thomas, John G. Bartlett, Mari...

Publish Year: 2012

[Safety analysis of sofosbuvir and ledipasvir for treating ...](#)

<https://pubmed.ncbi.nlm.nih.gov/26043900>

Introduction: The approval of sofosbuvir (SOF), a nucleotide analogue NS5B polymerase inhibitor, and ledipasvir (LDV), a NS5A inhibitor, marked a new chapter in IFN and ribavirin-free treatment of hepatitis C virus (HCV). This drug reduces adverse events associated with **IFN therapy**. Areas covered: The purpose of this paper is to evaluate the safety and efficacy of LDV/SOF.

Cited by: 15

Author: Yousef Fazel, Brian Lam, Pegah Golabi,...

Publish Year: 2015

PEOPLE ALSO ASK

How effective is protease inhibitor for hepatitis C?



What are the four protease inhibitors?



What is the treatment for Hep C?



What are the new medications for hepatitis C?



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

11,900 Results

Any time ▾

[Discussion on critical points for a tailored therapy to ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435970>

INTRODUCTION. **Hepatitis C virus** (HCV) is a single-stranded, positive-sense RNA **virus**, infecting approximately 71 million people worldwide []. The World Health Organization estimated the elimination of HCV **infection** by 2030, but this assumption is limited mainly by global HCV epidemiology and financial availability of drugs in different countries [].

Cited by: 8

Author: Nadia Marascio, Angela Quirino, Giorgi...

Publish Year: 2019

[Barriers to Hepatitis C Antiviral Therapy in HIV/HCV Co ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011402>

May 01, 2014 · Introduction. Uptake of **hepatitis C virus** (HCV) antiviral therapy remains low in patients with human immunodeficiency **virus** (HIV)/HCV co-**infection**; it is estimated that less than one-third of patients with HIV/HCV co-**infection** initiate HCV antiviral therapy. 1,2 This low **treatment** rate is reflective of the many ongoing challenges faced in **treating** this patient ...

Cited by: 18

Author: Christine U. Oramasionwu, Heather N. ...

Publish Year: 2014

[Antiviral treatment of hepatitis C | The BMJ](#)

<https://www.bmj.com/content/349/bmj.g3308.long> ▾

Jul 07, 2014 · **Hepatitis C virus** (HCV) **infection** is a substantial health problem worldwide. Most patients infected with HCV remain chronically infected, with an increased risk of cirrhosis and hepatocellular carcinoma. Although they are associated with toxicities and low sustained viral response rates, interferon alfa and ribavirin have been the mainstay of **treatment** until recently.

Cited by: 226

Author: Eoin R Feeney, Raymond T Chung

Publish Year: 2014

[Pharmacologic management of HCV treatment in patients with ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872158>

Nov 21, 2019 · Introduction. **Hepatitis C virus** (HCV) **infection** occurs in approximately 2.7 million Americans, causing cirrhosis, end-stage liver disease, and hepatocellular carcinoma in up to 20% of patients with chronic **infection** []. Approximately 5–30% of human immunodeficiency **virus**